Molecular electrostatic potential as a factor of drug-receptor recognition

Journal of Molecular Recognition

Volumn 16, Issue 4, 2003, Pages 191-202

  Dukhovich, Felix S ^a   Darkhovskii, Michael B ^a  

^a STATE RESEARCH INSTITUTE OF ORGANIC CHEMISTRY AND TECHNOLOGY   (Russian Federation)

Author keywords

Drug receptor recognition; Ligand receptor complex lifetime; Molecular electrostatic potential

Indexed keywords

CHEMISTRY, PHYSICAL; COMPUTER GRAPHICS; ELECTROSTATICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; RECEPTORS, DRUG; THERMODYNAMICS;

EID: 0042629679     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.616     Document Type: Article

References (50)

1. Andersen PH, Gronvald FC, Jansen JA. 1985. A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci. 37: 1971-1983.
2. Barlow RB. 1960. The cholinergic receptors. Biochem. Soc. Symp. 19: 46-53.
3. Baudry M, Martres MP, Schwartz JC. 1979. 3H-Domperidone: a selective ligand for dopamine receptors. Naunyn-Schmiedeberg's Arch. Pharmac. 308: 231-237.
4. Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A. 1984. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893.
5. 3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol. Pharmac. 12: 800-812.
6. Chamness GC, Costlow ME, McGuire WL. 1975. Estrogen receptor in rat liver and its dependence on prolactin. Steroids 26: 363-371.
7. 1/2 values in several nonaqueous solvents. Anal. Chem. 34: 1495-1501.
8. Chiou CY, Long JP, Cannon JG, Armstrong PD. 1969. The cholinergic effects and rates of hydrolysis of conformationally rigid analogs of acetylcholine. J. Pharmac. Exp. Ther. 166: 243.
9. Conway BE, Bockris JO'M, Ammar IA. 1951. The dielectric constant of the solution in the diffuse and Helmholtz double layers at a charged interface in aqueous solution. Trans. Faraday Soc. 47: 756-762.
10. 125l]iodomelatonin to characterize melatonin binding sites in chicken retina. Proc. Natl. Acad. Sci. USA 84: 3916-3920.
11. Dukhovich FS, Gorbatova EN, Kurochkin VK, Petrunin VA. 1999. The quantitative approach to definition of "super-low concentrations of drugs and poisons" concept. Russ. Chem. J. 43: 12-15 [in Russian].
12. Dukhovich FS, Gorbatova EN, Kurochkin VK. 2001. The relationship between the dispersion energy and the free energy of interaction of the molecular fragments of substituted glycolic acid N-methyl-4-piperidinyl esters with M-cholinergic receptors. Pharm. Chem. J. 35: 260-265.
13. Dukhovich FS, Gorbatova EN, Darhovskii MB, Kurochkin VK. 2002. Relationship between the dissociation constant and the lifetime for complexes of biologically active substances with receptors and enzymes. Pharm. Chem. J. 36: 248-254.
14. 125l]Iodomelatonin binding sites in hamster brain membranes: Pharmacological characteristics and regional distribution. Endocrinology 122: 1825-1833.
15. Enna SJ, Snyder SH. 1977. Influences of ions, enzymes, and detergents on gamma-aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol. Pharmac. 13: 442-453.
16. 2-adrenoceptors in the ventrolateral medulla. Eur. J. Pharmac. 134: 1-13.
17. Ernsting MJE, Rekker RF, Funcke ABH, Tersteeg HM, Nauta WT. 1959. Investigations on spasmolytic agents. Arzneim.-Forsch. 9: 573-576.
18. Faedda G, Kula NS, Baldessarini RJ. 1989. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue. Biochem. Pharmac. 38: 473-480.
19. Gribov LD, Mushtakova SP. 1999. Quantum Chemistry. Gardariki: Moscow, 1999; 179 [in Russian].
20. 3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur. J. Pharmac. 111: 191-199.
21. Houston DB, Howlett AC. 1993. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmac. 43: 17-22.
22. Hulme EC, Birdsall NJM, Burgen ASV, Mehta AP. 1978. The binding of antagonists to brain muscarinic receptors. Mol. Pharmac. 14: 737-750.
23. Laduron PM, Verwimp M, Leysen JE. 1979. Stereospecific in vitro binding of [3H]dexetimide to brain muscarinic receptors. J. Neurochem. 32: 421-427.
24. Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PA. 1981. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 28: 1015-1022.
25. 3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmac. 21: 301-314.
26. 3H]pirenzepine. J. Neurochem. 46: 274-279.
27. 3H]kainic acid binding sites in rat and human cerebellum. Eur. J. Pharmac. 56: 287-290.
28. Lyon RA, Davis KH, Titeler M. 1987. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol. Pharmac. 31: 194-199.
29. Mashkovskii MD. 2000. Drug Compounds, Vol. 1. Novaya volna: Moscow; 265, 281 [in Russian].
30. Mason SL, Reynolds GP. 1992. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur. J. Pharmac. 221: 397-398.
31. Meltzer HY, Hash JF. 1991. VII. Effects of antipsychotic drugs on serotonin receptors. Pharmac. Rev. 43: 587-604.
32. Michel AD, Whiting RL. 1987. Direct binding studies on ileal and cardiac muscarinic receptors. Br. J. Pharmac. 92: 755-767.
33. Paden CM, McEwen BS, Fishman J, Snyder L, De Groff V. 1982. Competition by estrogens for catecholamine receptor binding in vitro. J. Neurochem. 39: 512-520.
34. 3H-histamine in rat brain. Eur. J. Pharmac. 50: 443-444.
35. Peroutka SJ, Snyder SH. 1982. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1: 658.
36. Peroutka SJ, U'Prichard DC, Greenberg DA, Snyder SH. 1977. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology 16: 549-556.
37. Schaftenaar G, Noordik JH. 2000. Molden: a pre- and post-processing program for molecular and electronic structures. J. Comput.-Aided Mol. Des. 14: 123-134.
38. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JJ, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL, Dupuis M, Montgomery JA. 1993. J. Comput. Chem. 14: 1347; http://classic.chem.msu.su/gran/gamess/index.htm
39. Schwarzenbach G. 1936. Der Einfluss einer ionen ladung auf die Acidität einer Säure. Z. Phyz. Chem. 176: 133-161.
40. Seeman P, Niznik HB. 1988. Dopamine D1 receptor pharmacology. ISI Atlas Sci. Pharmac. 2: 161.
41. Shimizu H, Tatsuno T, Hirose A, Tanaka H, Kumasaka Y, Nakamura M. 1988. Characterization of the putative anxiolytic SM-3997 recognition sites in rat brain. Life Sci. 42: 2419-2427.
42. 3H]atipamezole as a radioligand for a2-adrenoceptors. Eur. J. Pharmac. 215: 109-117.
43. Skok VI, Selyanko AA, Derkach VA. 1987. Neuronal Acetylcholine Receptors. Nauka: Moscow [in Russian].
44. Squires RF, Braestrup C. 1977. Benzodiazepine receptors in rat brain. Nature 266: 732-735.
45. Stewart JJP. 1990. MOPAC: a semiempirical molecular orbital program. J. Comput. Aided Mol. Des. 4: 1-105.
46. 3H-Iofexidine to alpha-adrenoceptors in membranes from rat brain. Arch. Int. Pharmacodyn. Ther. 261: 23-35.
47. 3H]mepyramine. Proc. Natl Acad. Sci. USA 75: 6290-6294.
48. U' Prichard DC, Greenberg DA, Snyder SH. 1977. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol. Pharmac. 13: 454-473.
49. Webb JL. 1966. Enzyme And Metabolic Inhibitors, Vol. 1. Academic Press: New York.
50. Yamamura HI, Snyder SH. 1974. Muscarinic cholinergic binding in rat brain. Proc. Natl Acad. Sci. USA 71: 1725-1729.